Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) earlier this week outlined plans to expand into nuclear medicine with the launch of a network of specialized brain imaging clinics across the United States, beginning with its first site in Florida.
In an interview with Proactive, CEO Christopher Moreau said the company is targeting a significant gap in diagnostic capacity for Alzheimer’s disease, particularly as new therapies drive demand for early and accurate detection.
Moreau explained that Algernon Health Inc has partnered with Catalyst MedTech to deploy USFDA-approved PET scanners designed specifically for brain imaging.
He noted that the new devices are substantially smaller and more patient-friendly than traditional PET CT machines, which could improve accessibility and patient throughput. The company intends to focus exclusively on brain scans, enabling more efficient diagnosis of neurological conditions including Alzheimer’s, epilepsy, multiple sclerosis, and Parkinson’s disease.
Moreau highlighted that approximately 7 million Americans are believed to be living with Alzheimer’s, and recent approvals of antibody therapies that target amyloid plaques have created a clear need for PET-based diagnostic confirmation. He stated that patients must undergo a PET scan to qualify for these treatments, positioning Algernon Health Inc’s planned clinics as a critical component of the care pathway.
He further pointed out that the current installed base of PET CT scanners in the US is insufficient to meet rising demand, creating a strong market opportunity.
Moreau described the company’s model as a “low volume, special clinic” approach, focused on high-quality patient care and faster access to diagnostic services.
The selection of Florida as the first location reflects its large population of individuals aged 50 and above, a demographic with elevated Alzheimer’s risk. Moreau indicated that both PET scans and treatments are generally covered by Medicare, Medicaid, and private insurance, supporting the commercial viability of the model.
Looking ahead, Algernon Health Inc plans to replicate the clinic concept across multiple US locations. The first site is expected to begin operations within three to four months, serving as a launchpad for broader expansion.
The rollout of these clinics, combined with increasing demand driven by new therapies, represents a key near-term catalyst for the company as it positions itself within the growing nuclear medicine diagnostics market.